CRISPR Therapeutics AG
Open
$52.22
Prev. Close
$52.22
High
$52.22
Low
$52.18
Market Snapshot
$4.83B
-8.3
-4.35
$37.31M
393
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
emptyResult
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Recently from Cashu
CRISPR Therapeutics Strengthens Financial Strategy with $350 Million Convertible Notes Offering
CRISPR Therapeutics Reinforces Financial Strategy with Convertible Notes Offer CRISPR Therapeutics AG has outlined a significant move to enhance its financial footing by announcing plans to raise $350…
FDA Leadership Change Presents Opportunities and Challenges for Biopharmaceutical Innovation
FDA Leadership Transition Signals Implications for Biopharmaceutical Innovation The recent announcement from FDA Commissioner Marty Makary about the impending departure of Dr. Vinay Prasad from his ro…
FDA Leadership Changes Create Uncertainty for Biopharmaceuticals, Including CRISPR Therapeutics AG
FDA Leadership Transition Heights Regulatory Uncertainty for Biopharmaceuticals The recent announcement by FDA Commissioner Marty Makary regarding Dr. Vinay Prasad's upcoming departure from his positi…
CRISPR Therapeutics Advances Gene Editing Pipeline with Pioneering Therapies and Growing Investor Confidence
CRISPR Therapeutics Advances Gene Editing Technology Amidst Growing Pipeline CRISPR Therapeutics AG is making significant strides in the biopharmaceutical sector, particularly concerning its pioneerin…